Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tyrogenex
West Palm Beach, Florida, United Statestyrogenex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tyrogenex developed X‑82, an orally administered dual VEGFR/PDGFR inhibitor. Early clinical results showed that X‑82 was well tolerated in Phase I studies for advanced solid tumors and demonstrated preliminary anti-tumor activity. A Phase II study in wet AMD was planned. The company focused on developing targeted therapies with reduced toxicity compared to existing options[3].
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Brace Pharma
Beyond the preview
Go deeper on Tyrogenex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyrogenex.